Best Gene Editing CDMOs in South Korea
0
CDMOs tracked
0
Fully scored
Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.
Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|
What to evaluate in a Gene Editing CDMO
Editing components
Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.
Delivery modality
In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.
Ex vivo cell manufacturing
For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
What has driven South Korea's rise as a biologics manufacturing hub?
South Korea's biologics CDMO growth (2015-present) has been driven by three factors: (1) Samsung Biologics' massive Songdo capacity build (Plants 1-5 total >600,000L mammalian cell culture, one of the largest single-city concentrations of biologics capacity globally); (2) Celltrion's biosimilar-driven commercial capacity, exported globally; (3) national policy focus on biopharmaceutical export as a strategic industry. Korean CDMOs supplying US and EU markets typically hold MFDS + FDA + EMA certifications concurrently — the Signal Score's Quality Compliance pillar captures all three. For biologics programs specifically, South Korea offers commercial-scale capacity availability that is genuinely scarce in the US and EU.
How do Samsung Biologics and Celltrion compare on CDMO offerings?
Samsung Biologics operates primarily as a contract manufacturer (CDMO) with dedicated commercial biologics capacity at Songdo; Celltrion combines internal biosimilar development with CDMO services, with significant capacity dedicated to their own commercial products. For pure CDMO engagements, Samsung Biologics is typically the more scale-available option; for programs where biosimilar development experience is a plus, Celltrion's integrated model can add value. Both hold FDA and EMA certifications. Cross-check with the biologics CDMO ranking for the broader Korean biologics landscape and individual profile pages for facility-level detail.
South Korean CDMOs supplying US and EU markets — regulatory considerations
South Korean CDMOs supplying US and EU markets need active FDA and EMA GMP certifications on the specific facility. Both regulators have inspection experience with major Korean biologics sites, and inspection outcomes have generally been favorable. For programs supplying UK specifically, post-Brexit MHRA acceptance of MFDS + EMA-recognized inspections has continued under transitional arrangements — sponsors should confirm current MHRA policy at RFP stage. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Korean CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Gene Editing CDMOs — Frequently Asked Questions
What should I look for in a gene editing CDMO?
Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.
Why do gene editing programs use multiple CDMOs?
A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.
Related modalities